ET-02

N/A

Report date: 2023/01/08 19:06:10

Base Information

Drug NameET-02

Drug Alias NameET-02

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CD19

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusClinical

Highest Status in ChinaN/A

Originator CompaniesEdigene Inc

China Registration ClassN/A

Develop Information

Active CompaniesEdiGene Guangzhou Inc

Inactive CompaniesN/A

Active IndicationsLymphoma, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A